Calcium regulatory proteins and their alteration by transgenic approaches

American Journal of Cardiology

Volumn 83, Issue 12 A, 1999, Pages 89-91

  Dillmann, W H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLAMBAN; REGULATOR PROTEIN;

ANIMAL EXPERIMENT; AORTA CONSTRICTION; CALCIUM TRANSPORT; CLONING VECTOR; CONFERENCE PAPER; GENE EXPRESSION; GENE THERAPY; HEART HYPERTROPHY; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART MUSCLE RELAXATION; HEART PAPILLARY MUSCLE; HEART VENTRICLE CONTRACTILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOPLASMIC RETICULUM; TRANSGENE; TRANSGENIC MOUSE;

EID: 0033577958     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00268-4     Document Type: Conference Paper

References (16)

1. Carafoli E. Intracellular calcium homeostasis. Annu Rev Biochem. 56:1987;395-433.
2. McCall E., Ginsberg K.S., Bassani R.A., Shannon T.R., Qi M., Samarel A.M., Bers D.M. Ca flux, contractility, and excitation-contraction coupling in hypertrophic rat ventricular myocytes. Am J Physiol. 274:1998;H1348-H1360.
3. 2+ sparks . Cell Calcium. 20:1996;129-140.
4. Gwathmey J.K., Copelas L., MacKinnon R., Schoen F.J., Feldman M.D., Grossman W., Morgan J.P. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 61:1987;70-76.
5. Beuckelmann D.J., Nabauer M., Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 85:1992;1046-1055.
6. Meyer M., Schillinger W., Pieske B., Holubarsch C., Heilmann C., Posival H., Kuwajima G., Mikoshiba K., Just H., Hasenfuss G. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 92:1995;778-784.
7. 2+-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation. 90:1994;653-657.
8. 2+-ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J Mol Med. 74:1996;321-332.
9. 2+-ATPase in failing and nonfailing human hearts. Cardiovasc Res. 31:1996;625-632.
10. Hajjar R.J., Schmidt U., Matsui T., Guerrero J.L., Lee K.H., Gwathmey J.K., Dec G.W., Semigran M.J., Rosenzweig A. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA. 95:1998;5251-5256.
11. Luo W., Grupp I.L., Harrer J., Ponniah S., Grupp G., Duffy J.J., Doetschman T., Kranias E.G. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res. 75:1994;401-409.
12. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest. 10:1997;380-390.
13. 2+ transients. Circulation. 96:1997;400-403.
14. 2+ ATPase of cardiac sarcoplasmic reticulum are critical for functional association with phospholamban. J Biol Chem. 269:1994;22929-22932.
15. 2+ ATPase of sarcoplasmic reticulum. J Biol Chem. 269:1994;3088-3094.
16. 2+-ATPase activity and cardiac myocyte contractility. Circulation 1999; in press.